PITTSBURGH, Feb. 9, 2021 /PRNewswire/ -- Viatris Inc.
(NASDAQ: VTRS) today announced that it will host a conference
call at 8 a.m. ET on Monday, Feb. 22 to discuss
2021 financial guidance.
The briefing can be accessed live by calling (855)
493-3607 or (346) 354-0950 for international callers
(ID#: 3235536) or at the following address on the company's
website: investor.viatris.com. A slide presentation and
replay of the webcast also will be available on the
website.
As previously announced, Viatris will hold its inaugural
Investor Day virtually on Monday, March 1,
2021. The event will begin at 8:30
a.m. ET. CEO Michael
Goettler, President Rajiv
Malik, Chief Financial Officer Sanjeev Narula and several other members of the
leadership team will present a deep dive into the company's
strategy to optimize total shareholder return, while delivering on
its mission to empower people worldwide to live healthier at every
stage of life.
Interested parties will be able to access a live webcast of the
Investor Day event via the investor relations section
of Viatris' website at investor.viatris.com. A
replay and archived edition of the presentation will be available
following the event.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare
company, empowering people worldwide to live healthier at every
stage of life. We provide access to medicines, advance
sustainable operations, develop
innovative solutions and leverage our
collective expertise to connect more people to more
products and services through our one-of-a-kind Global
Healthcare GatewayTM. Formed in November 2020 through the combination of Mylan
and Pfizer's Upjohn business, Viatris brings together
scientific, manufacturing and distribution expertise with
proven regulatory, medical and commercial capabilities to
deliver high-quality medicines to patients in more than 165
countries and territories. Viatris' portfolio comprises more
than 1,400 approved molecules across a wide range of therapeutic
areas, spanning both non-communicable and infectious diseases,
including globally recognized brands, complex generic and branded
medicines, a growing portfolio of biosimilars and a variety of
over-the-counter consumer products. With a global workforce
of approximately 45,000, Viatris is headquartered in
the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter
at @ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements
This press release
includes statements that constitute "forward-looking statements."
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements about the Company's
guidance and the presentation of the Company's strategy to optimize
total shareholder return, while delivering on its mission to
empower people worldwide to live healthier at every stage of life.
Because forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such statements. Factors that could
cause or contribute to such differences include, but are not
limited to: the potential impact of public health outbreaks,
epidemics and pandemics, including the ongoing challenges and
uncertainties posed by the COVID-19 pandemic; the integration of
Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn
Business"), which combined to form Viatris (the "Combination") and
the implementation of our global restructuring initiatives being
more difficult, time consuming or costly than expected, or being
unsuccessful; the ability to achieve expected benefits,
synergies and operating efficiencies in connection with the
Combination or its restructuring initiatives within the expected
timeframe or at all; actions and decisions of healthcare and
pharmaceutical regulators; changes in healthcare and pharmaceutical
laws and regulations in the U.S. and abroad; any regulatory, legal
or other impediments to Viatris' ability to bring new products to
market; Viatris' or its partners' ability to develop, manufacture
and commercialize products; the scope, timing and outcome of any
ongoing legal proceedings and the impact of any such proceedings;
any significant breach of data security or data privacy or
disruptions to our information technology systems; risks associated
with international operations, including our operations
in China; the ability to protect intellectual property and
preserve intellectual property rights; changes in third-party
relationships; the effect of any changes in Viatris' or its
partners' customer and supplier relationships and customer
purchasing patterns; the impacts of competition; changes in the
economic and financial conditions of Viatris or its partners;
uncertainties and matters beyond the control of management; and the
other risks Viatris' filings with the Securities and Exchange
Commission. Viatris routinely uses its website as a means of
disclosing material information to the public in a broad,
non-exclusionary manner for purposes of the SEC's Regulation Fair
Disclosure (Reg FD). Viatris undertakes no obligation to update
these statements for revisions or changes after the date of this
release other than as required by law.
View original
content:http://www.prnewswire.com/news-releases/viatris-inc-to-hold-conference-call-on-monday-feb-22-2021-to-discuss-2021-financial-guidance-301225269.html
SOURCE Viatris Inc.